Coherus Biosciences Falls 30% After FDA Response Letter

Coherus Biosciences Inc CHRS shares are trading lower by $6.50 (30 percent) at $14.15 percent in Monday's session.

The Street isn't acting favorably to the FDA's Complete Response Letter for its application for its CHS-1701. In the letter, the FDA has requested additional information in which the company has pledged to provide.

After a much lower open, Coherus immediately bottomed at $14.05 and managed a brief rally to $14.98. That low coincides with its early July 2016 low at $14.00. It has been unable to sustain that rally and is drifting back towards the lows for the session.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!